MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $31 avg across 9 analysts.
Buy-rated share 46% → 52% over ~3 months (+6pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $0.17 | $0.37 | +116.6% |
| Apr 2026 | $0.18 | $0.26 | +46.3% |
| Feb 2026 | $0.18 | $0.27 | +48.2% |
| Oct 2025 | $0.47 | $0.22 | -53.2% |
| Jul 2025 | $0.48 | $0.23 | -52.1% |
| Apr 2025 | $0.47 | $0.27 | -42.6% |
| Feb 2025 | $0.47 | $0.23 | -51.1% |
| Oct 2024 | $0.17 | $0.15 | -11.8% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
No recent open-market insider transactions.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.0B— | $2.2B+12.1% | $2.4B+8.7% | $2.6B+7.7% | $2.7B+4.2% |
| EPS (dil.) | $0.45— | $0.63+40.0% | $0.85+34.9% | $0.74-12.9% | $0.96+29.7% |
| Free Cash Flow | $745M— | $816M+9.5% | $886M+8.6% | $862M-2.7% | $963M+11.7% |
| Gross Margin | 61.0% | 60.9%-0.1pp | 59.9%-1.1pp | 59.0%-0.8pp | 3.7%-55.3pp |
| Operating Margin | 27.6% | 29.1%+1.5pp | 28.8%-0.4pp | 28.3%-0.5pp | 27.1%-1.2pp |
| Net Margin | 13.1% | 17.1%+4.0pp | 21.4%+4.2pp | 17.3%-4.0pp | 21.5%+4.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 4.7%/yr (revenue basis).
Base free cash flow $904M (avg FY2023–FY2025; latest year $963M) · equity value $17.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 58 for INVH suggests a moderately attractive stock, with the short-term score slightly outpacing the long-term score. INVH scores high on risk factors, with a relatively low beta and volatility, but trails in growth, with revenue growth of 4.2% and EPS growth of 29.7%. The stock exhibits strong momentum, with a 6.0% return over the past three months, and trades at a P/E of 27.7, which is somewhat elevated. Overall, the score reflects a mix of positive and negative factors, with no single category dominating the assessment.